PUBLISHER: DelveInsight | PRODUCT CODE: 1462269
PUBLISHER: DelveInsight | PRODUCT CODE: 1462269
"Buntanetap Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about buntanetap for Parkinson's disease in the seven major markets. A detailed picture of the buntanetap for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the buntanetap for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the buntanetap market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
Buntanetap (previously known as ANVS401 or posiphen) is a synthetically produced oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which lowers the level of neurotoxic proteins and consequently less toxicity in the brain. Buntanetap is an orally available small molecule, and its unique mechanism of action allows it to inhibit multiple neurotoxic proteins-APP/AB (APP), tau/phospho-tau (tau), and a-Synuclein (aSYN)-that is one of the main causes of neurodegeneration at once and improve motor function.
The US FDA has green-lighted the continued development of Buntanetap into phase III for early and advanced Parkinson's disease. Presently buntanetap is being studied in a Phase III early Parkinson's disease study and the company expects to complete the trial by the end of 2023. The company is also developing buntanetap for Alzheimer's disease and other neurodegenerative conditions.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Buntanetap Analytical Perspective by DelveInsight
This report provides a detailed market assessment of buntanetap for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of buntanetap for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.